Enteral Supplementation With Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the Treatment of Hypophosphatemia.

Exclusion Criteria

• •1. Pregnant and lactating women;
• •2. Patients with contraindications for enteral administration, such as acute upper gastrointestinal bleeding, mechanical intestinal obstruction, severe acute pancreatitis, digestive tract fistula, gastrointestinal dysfunction, intra-abdominal hypertension, enteral feeding intolerance, or continuous gastrointestinal decompression;
• •3. Expected ICU stay ≤96 hours;
• •4. Known allergy to any component of the investigational drug or drugs with a similar chemical structure;
• •5. Severe renal impairment: estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m²;
• •6. Subjects with hyperthyroidism requiring clinical intervention;
• •7. Subjects requiring sodium restriction;
• •8. Other conditions deemed by the investigator as unsuitable for inclusion.